United Therapeutics Corporation to Post Q3 2017 Earnings of $3.79 Per Share, Wedbush Forecasts (NASDAQ:UTHR)
United Therapeutics Corporation (NASDAQ:UTHR) – Wedbush increased their Q3 2017 earnings per share estimates for United Therapeutics Corporation in a research report issued on Monday. Wedbush analyst L. Moussatos now expects that the biotechnology company will post earnings per share of $3.79 for the quarter, up from their prior estimate of $3.77. Wedbush has a “Outperform” rating and a $213.00 price objective on the stock. Wedbush also issued estimates for United Therapeutics Corporation’s Q4 2017 earnings at $3.51 EPS, Q1 2018 earnings at $3.61 EPS, Q2 2018 earnings at $3.15 EPS, Q3 2018 earnings at $3.31 EPS and Q4 2018 earnings at $3.28 EPS.
A number of other equities research analysts also recently weighed in on the company. ValuEngine upgraded United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. HC Wainwright restated a “hold” rating and set a $95.00 price target on shares of United Therapeutics Corporation in a research report on Monday, April 17th. BidaskClub downgraded United Therapeutics Corporation from a “buy” rating to a “hold” rating in a research report on Wednesday, July 19th. Finally, Jefferies Group LLC restated a “sell” rating and set a $116.00 price target on shares of United Therapeutics Corporation in a research report on Wednesday, April 12th. Six equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $134.50.
COPYRIGHT VIOLATION WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/08/09/united-therapeutics-corporation-to-post-q3-2017-earnings-of-3-79-per-share-wedbush-forecasts-nasdaquthr.html.
Shares of United Therapeutics Corporation (UTHR) opened at 131.04 on Tuesday. The firm has a 50 day moving average price of $130.70 and a 200-day moving average price of $136.13. United Therapeutics Corporation has a 52-week low of $110.90 and a 52-week high of $169.89. The company has a market cap of $5.69 billion, a price-to-earnings ratio of 15.20 and a beta of 1.51.
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of $3.61 by $4.86. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company had revenue of $444.60 million during the quarter, compared to the consensus estimate of $391.53 million. During the same quarter last year, the firm posted $4.42 EPS. The company’s quarterly revenue was up 7.8% on a year-over-year basis.
Several hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its stake in United Therapeutics Corporation by 1.8% in the first quarter. JPMorgan Chase & Co. now owns 122,497 shares of the biotechnology company’s stock valued at $16,583,000 after buying an additional 2,223 shares during the last quarter. Clarity Capital KCPS Ltd. acquired a new stake in United Therapeutics Corporation during the first quarter valued at about $230,000. Argent Capital Management LLC boosted its stake in United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock valued at $343,000 after buying an additional 60 shares during the last quarter. Greylin Investment Mangement Inc. boosted its stake in United Therapeutics Corporation by 42.3% in the second quarter. Greylin Investment Mangement Inc. now owns 2,975 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 885 shares during the last quarter. Finally, Nuveen Asset Management LLC boosted its stake in United Therapeutics Corporation by 222.1% in the first quarter. Nuveen Asset Management LLC now owns 64,507 shares of the biotechnology company’s stock valued at $8,733,000 after buying an additional 44,481 shares during the last quarter.
In related news, CEO Martine A. Rothblatt sold 1,248 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $126.41, for a total value of $157,759.68. Following the sale, the chief executive officer now directly owns 2,317 shares of the company’s stock, valued at $292,891.97. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christopher Causey sold 590 shares of the firm’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $132.61, for a total value of $78,239.90. Following the completion of the sale, the director now directly owns 3,875 shares in the company, valued at $513,863.75. The disclosure for this sale can be found here. Insiders sold 23,758 shares of company stock worth $3,058,699 over the last three months. 7.80% of the stock is owned by insiders.
United Therapeutics Corporation announced that its board has initiated a stock buyback program on Thursday, April 27th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the biotechnology company to purchase up to 4.6% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Stock Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related stocks with our FREE daily email newsletter.